Axogen (AXGN) Cash & Equivalents (2010 - 2026)

Axogen's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $82.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 356.75% year-over-year to $82.7 million in Q1 2026; TTM through Mar 2026 was $82.7 million, a 356.75% increase from a year earlier, with the FY2025 full-year figure at $35.5 million, up 29.01% from the prior year.
• Cash & Equivalents rose to $82.7 million in Q1 2026 per AXGN's latest filing, from $35.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $82.7 million in Q1 2026 and bottomed at $7.7 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $19.2 million (2024), against an average of $24.1 million.
• Across the five-year window, Cash & Equivalents tumbled 77.73% in 2022 and surged 356.75% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $15.3 million in 2022, then surged by 102.98% to $31.0 million in 2023, then decreased by 11.18% to $27.6 million in 2024, then advanced by 29.01% to $35.5 million in 2025, then jumped by 132.51% to $82.7 million in 2026.
• Per Business Quant, the three latest AXGN Cash & Equivalents figures stand at $82.7 million (Q1 2026), $35.5 million (Q4 2025), and $23.9 million (Q3 2025).